Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1238-1245

  Guzmán Fulgencio, María ^a   Jiménez, Jose Luis ^b   Berenguer, Juan ^b   Fernández Rodríguez, Amanda ^a   López, Juan Carlos ^b   Cosín, Jaime ^b   Miralles, Pilar ^b   Micheloud, Dariela ^a,b   Muñoz Fernández, Ma Ángeles ^b,c   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c CSIC   (Spain)

Author keywords

AIDS; Chronic hepatitis C; Cytokines; Interferon; Sustained virological response

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 28B; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENOTYPE; HELPER CELL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TH2 CELL; TH22 CELL; TH9 CELL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-6; INTERLEUKIN-9; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT FAILURE; VIRAL LOAD;

EID: 84859584999     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr595     Document Type: Article

References (53)

1. Alter MJ, Seeff LB, Bacon BR et al. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004; 141: 715-7.
2. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
3. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.
4. Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590-8.
5. Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008; 47: 94-101.
6. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112: 1557-69.
7. Perumal NB, Kaplan MH. Regulating Il9 transcription in T helper cells. Trends Immunol 2011; 32: 146-50.
8. Eyerich S, Eyerich K, Cavani A et al. IL-17 and IL-22: siblings, not twins. Trends Immunol 2010; 31: 354-61.
9. Yoneda S, Umemura T, Katsuyama Y et al. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011; 203: 1087-95.
10. Wan L, Kung YJ, Lin YJ et al. Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-alpha. Biochem Biophys Res Commun 2009; 379: 855-60.
11. Gramenzi A, Andreone P, Loggi E et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat 2005; 12: 525-30.
12. Cacciarelli TV, Martinez OM, Gish RG et al. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996; 24: 6-9.
13. Doehring A, Hofmann WP, Schlecker C et al. Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antivir Ther 2010; 15: 1099-106.
14. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature Genetics 2009; 41: 1105-9.
15. Clausen LN, Weis N, Astvad K et al. Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. J Viral Hepat 2011; 18: e66-74.
16. Tsai SL, Liaw YF, Chen MH et al. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449-58.
17. MacDonald AJ, Duffy M, Brady MT et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis 2002; 185: 720-7.
18. Nattermann J, Vogel M, Berg T et al. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology 2007; 46: 1016-25.
19. Morgan TR, Lambrecht RW, Bonkovsky HL et al. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008; 49: 548-56.
20. Basu A, Meyer K, Lai KK et al. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 2006; 349: 347-58.
21. Funaoka Y, Sakamoto N, Suda G et al. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol 2011; 85: 5986-94.
22. Suda G, Sakamoto N, Itsui Y et al. IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. Virology 2010; 407: 80-90.
23. Ouyang W, Rutz S, Crellin NK et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29: 71-109.
24. Marin-Serrano E, Rodriguez-Ramos C, Diaz F et al. Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat 2006; 13: 230-4.
25. Diaz-Valdes N, Manterola L, Belsue V et al. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 2010; 53: 23-31.
26. Brooks DG, Trifilo MJ, Edelmann KH et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; 12: 1301-9.
27. Brockman MA, Kwon DS, Tighe DP et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 2009; 114: 346-56.
28. Weng HL, Liu Y, Chen JL et al. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology 2009; 50: 230-43.
29. Wu B, Huang C, Kato-Maeda M et al. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol 2008; 126: 202-10.
30. Bermejo-Martin J, Ortiz de Lejarazu R, Pumarola T et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Critical Care 2009; 13: R201.
31. Semple MG, Dankert HM, Ebrahimi B et al. Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P. PLoS One 2007; 2: e1038.
32. Elyaman W, Bradshaw EM, Uyttenhove C et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA 2009; 106: 12885-90.
33. Larrea E, Garcia N, Qian C et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-7.
34. Hong F, Nguyen VA, Gao B. Tumor necrosis factor alpha attenuates interferon alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J 2001; 15: 1595-7.
35. Kim KA, Lin W, Tai AW et al. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol 2009; 50: 705-11.
36. Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009; 123: 1004-11.
37. Crowe CR, Chen K, Pociask DA et al. Critical role of IL-17RA in immunopathology of influenza infection. J Immunol 2009; 183: 5301-10.
38. Zhang JY, Song CH, Shi F et al. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One 2010; 5: e13869.
39. Salgado M, Rallon NI, Rodes B et al. Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. Clin Immunol 2011; 139: 110-4.
40. Chung H, Watanabe T, Kudo M et al. Hepatitis C virus core protein induces homotolerance and cross-tolerance to Toll-like receptor ligands by activation of Toll-like receptor 2. J Infect Dis 2010; 202: 853-61.
41. Witte E, Witte K, Warszawska K et al. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev 2010; 21: 365-79.
42. Park O, Wang H, Weng H et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 2011; 54: 252-61.
43. Zenewicz LA, Yancopoulos GD, Valenzuela DM et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647-59.
44. Dambacher J, Beigel F, Zitzmann K et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 2008; 41: 209-16.
45. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008; 128: 133-47.
46. Trapero-Marugan M, Garcia-Buey L, Munoz C et al. Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. Aliment Pharmacol Ther 2006; 24: 117-28.
47. Shirakawa H, Matsumoto A, Joshita S et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-60.
48. Barker E, Mackewicz CE, Levy JA. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival. Proc Natl Acad Sci USA 1995; 92: 11135-9.
49. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
50. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
51. Urban TJ, Thompson AJ, Bradrick SS et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-96.
52. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-9.
53. de Jager W, Bourcier K, Rijkers GT et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunology 2009; 10: 52.